Recent Updates
Recently added Catalysts
RCEL Positive Sentiment

AVITA Medical to Present at the Piper Sandler 37ᵗʰ Annual Healthcare Conference

Key Takeaway: AVITA Medical, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The presentation is scheduled for 8:30 a.m. EST, and management will be available for one-on-one meetings with registered investors. A live audio webcast of the presentation will be accessible on the company's website.
Price reaction · baseline $3.75 (2025-11-24 close) · hit after-hours · clean, no other RCEL news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • AVITA Medical will present at a significant healthcare conference.
  • Management will engage with investors through one-on-one meetings.
  • The RECELL System offers innovative solutions for wound care.

Full Press Release Details

VALENCIA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 8:30 a.m. EST. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.
A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com/events-and-presentations. A replay of the webcast will be available following the conclusion of the event.

About AVITA Medical, Inc.

AVITA Medical®is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL®System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the rights to manufacture and exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, and excluding RECELL GO, in Australia and Japan.
To learn more, visit  www.avitamedical.com.

Investor & Media Contact:Ben AtkinsPhone +1-805 341 1571investor@avitamedical.com|media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Frequently Asked Questions

When will AVITA Medical present at the conference?

AVITA Medical will present on December 4, 2025, at 8:30 a.m. EST.

How can investors attend the presentation?

Investors can register for the conference to attend the presentation and one-on-one meetings.

Where can I watch the presentation live?

The live audio webcast will be available on AVITA Medical's website.

What is the RECELL System?

The RECELL System is a wound care technology that uses a patient's skin to create Spray-On Skin Cells.

Last updated: Nov 24, 2025